Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.
Please provide your email address to receive an email when new articles are posted on . Risk for developing kidney failure outpaced death for adults with diabetes and low eGFR. Lower eGFR, older age, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback